4th Quarter - Report

HOSPIRA, INC. for HOSPIRA INC

Firm
Client
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act

LobbyistCovered position, as disclosed
JULIANA REED —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 232 (113th)

Budget/Appropriations BUD

S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)

LobbyistCovered position, as disclosed
JULIANA REED —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3547 (113th), H.R. 2725 (113th), S. 1413 (113th)

Pharmacy PHA

Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act

LobbyistCovered position, as disclosed
JULIANA REED —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3204 (113th), S. 959 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.